



March 3, 2021

Establish NeuroDiscovery Lab in the Boston Area to Strengthen the Discovery of Drug Targets for the Central Nervous System Disorders

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, Japan; President & Representative Director; Hiroaki Ueno; hereafter, "MTPC") announced today that MTPC will establish NeuroDiscovery Lab, a new satellite research base in the Boston area of the U.S. on April 1, 2021, in order to strengthen the ability to discover novel drug targets in the central nervous system disease area that can be developed globally with a focus on the U.S. market.

NeuroDiscovery Lab is located in SmartLabs in the biotechnology hub of Cambridge, near Boston, Massachusetts, USA, and will operate as a research base for discovering new drug targets in the central nervous system disease area, particularly in amyotrophic lateral sclerosis (ALS). In the MTPC Group's Medium-Term Management Plan 2021-2025, MTPC will focus on the research and development to create a drug pipeline for precision medicine in the central nervous system and the immuno-inflammation treatments. NeuroDiscovery Lab will play a central role in early drug discovery research focused on precision medicine in the central nervous system. SmartLabs is a life-science managed research center that provides pharma-grade research environment, in which about 40 companies, mainly pharmaceutical R&D companies, operate. SmartLabs research environments can be rapidly reconfigured to meet the infrastructure needs of a fast evolving drug discovery initiative such as NeuroDiscovery Lab. Establishing a research base in SmartLabs enables MTPC to explore opportunities for novel drug discovery and further collaboration with industry and academia in the Boston ecosystem.

MTPC Group companies contribute to research for novel treatments for diseases with unmet medical needs through joint research and collaboration with various academia and companies. MTPC aims to be a healthcare company that provides optimal medical care to every person by establishing NeuroDiscovery Lab to create a drug pipeline focused on potential precision medicine treatments for central nervous system diseases.

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department

Media contacts: TEL:+81 6 6205 5119